FDA Approves New Drug for Urothelial Carcinoma

AACN Bold Voices 8(8):p 17, August 2016.

Tecentriq (atezolizumab) is the first in its class of drugs, called PD-1/PD-L1 inhibitors, to be approved for this cancer.